• Test code: 06183
  • Turnaround time:
    10–21 calendar days (14 days on average)
  • Preferred specimen:
    3mL whole blood in a purple-top tube
  • Alternate specimens:
    DNA or saliva/assisted saliva
  • Sample requirements
  • Request a sample kit

Invitae Wilson Disease Test

Test description

The Invitae Wilson Disease Test analyzes the ATP7B gene, pathogenic variants in which can cause decreased biliary excretion of copper, reduced incorporation of copper into apoceruloplasmin, and the overall accumulation of copper in the body.

Affected individuals present with low serum copper and ceruloplasmin levels and increased urinary copper excretion. Molecular genetics are necessary to confirm the diagnosis of Wilson disease. Medical management with chelating agents and zinc are useful to reduce symptoms. Liver transplantation is undertaken for patients who are not responsive to medical management.

Order test

Primary panel (1 gene)
  • Wilson disease

Wilson disease is a disorder of copper metabolism. Patients suspected of having Wilson disease often have liver disease (40%), neurologic disease (40%), and psychiatric disturbance (20%); most have the eye finding of Kayser Fleischer rings. Diagnosis can occur during a wide range of ages; most often, it is between 6 and 50 years of age. Younger patients are often identified due to liver disease. Other findings include renal involvement, arthritis, osteoporosis, pancreatitis, cardiomyopathy, and sunflower cataracts. Hepatocellular carcinoma rarely develops.

Affected individuals present with increased urinary copper excretion and low serum copper and ceruloplasmin levels. Molecular genetics are necessary to confirm a diagnosis of Wilson disease. Medical management with chelating agents and zinc are useful to reduce symptoms. Liver transplantation is undertaken for patients who are not responsive to medical management.

For patients with clinical symptoms of Wilson disease, sequence variants in the gene ATP7B are identified in more than 98% of patients. Deletions/duplications in this gene are rare.

Wilson disease is inherited in an autosomal recessive pattern.

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
ATP7B NM_000053.3